FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * RODRIGUEZ RAUL R					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]									tionship of R all applicabl Director		Person(s) to Issuer 10% Ov	vner	
(Last)	(First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/26/2023								X	Officer (g below)			Other (s below)	specify	
RIGEL PHARMACEUTICALS, INC.															CEO, I	Presid	ent		
611 GATEWAY BLVD, SUITE 900				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SOUTH SAN FRANCISCO	('Δ	ç	94080										X	Form filed	•	•	ng Person ne Reportin	g Person	
(City)	(State	e) (.	Zip)																
		T	Γable I - Noι	า-Deriva	tive S	ecuritie	s Acq	uired, D	isp	osed o	f, or E	Benefic	ially Ow	ned					
Date				2. Transac Date (Month/Da	Execution Da		n Date,	e, Transaction Dispose Code (Instr.			rities Acquired (A) or ed Of (D) (Instr. 3, 4 and 5			5. Amount Securities Beneficially Following I	Owned or li Reported (Ins		Direct (D)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 01/20				01/26/2	26/2023		A		300,000(1)		A	\$0	1,701,053(2)			D			
Common Stock 02/0				02/06/2	06/2023		S ⁽³⁾		20,340		D	\$1.75	1,680,713			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date if any (Month/Day/Yea	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour Securities Underly Derivative Security 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	de V	(A)	(D)	Date Exercisable		xpiration ate	Title	- 1	Amount or Number of Shares		Transacti (Instr. 4)	on(s)			
Employee Stock Option (right to buy)	\$1.87	01/26/2023		A		600,000		(4)	01	1/26/2033		nmon ock	600,000	\$0	600,00	00	D		
Explanation of F	Responses:																		

- 1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024.
- 2. Includes 9,277 shares acquired under the Issuer's stock purchase plan.
- 3. These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by
- 4. The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period.

/s/ Raymond Furey (Attorney-in-02/07/2023 Fact)

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.